Sprint Financial Statements From 2010 to 2024
SPRINT Stock | SEK 1.35 0.05 3.57% |
Check Sprint Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sprint main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Sprint financial statements analysis is a perfect complement when working with Sprint Bioscience Valuation or Volatility modules.
Sprint |
Sprint Bioscience AB Company Return On Equity Analysis
Sprint Bioscience's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sprint Bioscience Return On Equity | -1.09 |
Most of Sprint Bioscience's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sprint Bioscience AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition |
Based on the latest financial disclosure, Sprint Bioscience AB has a Return On Equity of -1.0926. This is 95.44% lower than that of the Healthcare sector and notably lower than that of the Drug Manufacturers - Specialty & Generic industry. The return on equity for all Sweden stocks is notably higher than that of the company.
Sprint Bioscience Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sprint Bioscience's current stock value. Our valuation model uses many indicators to compare Sprint Bioscience value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sprint Bioscience competition to find correlations between indicators driving Sprint Bioscience's intrinsic value. More Info.Sprint Bioscience AB is currently regarded as top stock in return on equity category among related companies. It is currently regarded as top stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sprint Bioscience by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sprint Bioscience's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sprint Bioscience's earnings, one of the primary drivers of an investment's value.About Sprint Bioscience Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Sprint Bioscience income statement, its balance sheet, and the statement of cash flows. Sprint Bioscience investors use historical funamental indicators, such as Sprint Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sprint Bioscience investors may use each financial statement separately, they are all related. The changes in Sprint Bioscience's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sprint Bioscience's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Sprint Bioscience Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Sprint Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Sprint Bioscience AB develops pharmaceutical products in the areas of cancer and metabolism. Sprint Bioscience AB was founded in 2009 and is based in Huddinge, Sweden. Sprint Bioscience operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sprint Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sprint Bioscience's short interest history, or implied volatility extrapolated from Sprint Bioscience options trading.
Currently Active Assets on Macroaxis
Check out the analysis of Sprint Bioscience Correlation against competitors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Sprint Stock analysis
When running Sprint Bioscience's price analysis, check to measure Sprint Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sprint Bioscience is operating at the current time. Most of Sprint Bioscience's value examination focuses on studying past and present price action to predict the probability of Sprint Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sprint Bioscience's price. Additionally, you may evaluate how the addition of Sprint Bioscience to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |